AI Science Tracker
EN

Department of Dermatology, Shengjing Hospital, China Medical University, Shenyang, China

1 discovery from 2026

Discoveries

Multimodal profiling uncovers an aging-associated ETS1-MYO1B vascular niche responsive to ipragliflozin.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: An ML age-clock combined with multimodal tissue and cell analyses identified an aging-associated ETS1-MYO1B vascular niche and examined its response to ipragliflozin in the reported models.

Technology: the learned operation enabling the specific result: The ML age-clock and multimodal analyses identify an aging-associated vascular niche, with human-tissue, cell-model and animal validation reported.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
the learned operation enabling the specific result: The ML age-clock and multimodal analyses identify an aging-associated vascular niche, with human-tissue, cell-model and animal validation reported.
Limitation / still unknown
Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.3389/fcell.2026.1968248

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.